Vericel Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Vericel hat ein Gesamteigenkapital von $233.9M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $356.7M bzw. $122.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$110.65m
Eigenkapital	US$233.90m
Gesamtverbindlichkeiten	US$122.77m
Gesamtvermögen	US$356.66m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Apr 26

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Mar 02

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Feb 02

Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Aug 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VCELDie kurzfristigen Aktiva des Unternehmens ($189.7M) übersteigen seine kurzfristigen Passiva ($36.5M).

Langfristige Verbindlichkeiten: VCELDie kurzfristigen Vermögenswerte des Unternehmens ($189.7M) übersteigen seine langfristigen Verbindlichkeiten ($86.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VCEL ist schuldenfrei.

Schulden abbauen: VCEL hatte vor 5 Jahren keine Schulden.

Schuldendeckung: VCEL hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: VCEL hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Vericel Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

CEO, President & Director notifies of intention to sell stock

Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

New minor risk - Shareholder dilution

Vericel Corporation Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director exercised options to buy US$1.2m worth of stock.

It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year

Vericel Corporation to Report Q1, 2024 Results on May 08, 2024

CEO, President & Director notifies of intention to sell stock

Vericel Corporation, Annual General Meeting, May 01, 2024

CEO, President & Director notifies of intention to sell stock

Senior VP recently sold US$368k worth of stock

Senior VP notifies of intention to sell stock

Price target increased by 11% to US$52.07

Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?

Full year 2023 earnings: EPS exceeds analyst expectations

Vericel Corporation Provides Earnings Guidance for the Fiscal Year 2024

CEO, President & Director notifies of intention to sell stock

Vericel Corporation to Report Q4, 2023 Results on Feb 29, 2024

Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%

Price target increased by 7.9% to US$46.23

CEO, President & Director notifies of intention to sell stock

Vericel Corporation Provides Earnings Guidance for the Year 2024

Vericel Corporation Provides Earnings Guidance for the Fourth Quarter and Full-Year 2023

Chief Operating Officer exercised options and sold US$492k worth of stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Vericel Corporation Provides Total Net Revenue Guidance for 2023

Vericel Corporation to Report Q3, 2023 Results on Nov 08, 2023

Vericel Corporation Announces U.S. Commercial Availability of NexoBrid (Anacaulase-Bbb) for the Treatment of Severe Thermal Burns in Adults

Consensus estimates of losses per share improve by 15%

Vericel Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Vericel Corporation to Report Q2, 2023 Results on Aug 02, 2023

Price target increased by 7.9% to US$40.75

Consensus EPS estimates fall by 12%, revenue upgraded

Vericel Corporation Raises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit

Consensus EPS estimates fall by 48%

Chief Operating Officer exercised options and sold US$95k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 7.1% to US$36.67

Vericel Corporation to Report Q4, 2022 Results on Feb 23, 2023

CEO, President & Director exercised options and sold US$100k worth of stock

CEO, President & Director notifies of intention to sell stock

Vericel Corporation Announces Accelerated Launch Timeline for MACI Arthroscopic Program

Vericel Corporation Provides Revenue Guidance for the Full-Year 2022

Vericel Announces Fda Approval of Nexobrid for the Treatment of Severe Thermal Burns in Adults

Price target increased to US$37.00

Price target decreased to US$33.25

Price target decreased to US$38.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vericel Corporation Provides Earnings Guidance for the Full-Year 2022

Vericel Corporation to Report Q3, 2022 Results on Nov 09, 2022

Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vericel Corporation Announces Revenue Guidance for the Full Year of 2022

Vericel Q2 2022 Earnings Preview

Vericel Corporation Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America of Patients with Large Posterior Trunk Burns Treated with Epicel

Vericel Corporation to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$45.20

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Vericel Corporation Reaffirms Earnings Guidance for the Year 2022

Now 21% undervalued after recent price drop

Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Vericel - A Disruptive Business With Years Of Growth Remaining

Chief Medical Officer exercised options and sold US$305k worth of stock

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS exceeds analyst expectations

Vericel Corporation Announces Appointment of Jonathan Siegal as Principal Accounting Officer

CEO, President & Director exercised options and sold US$135k worth of stock

CEO, President & Director exercised options and sold US$115k worth of stock

Vericel Corporation to Report Q4, 2021 Results on Feb 24, 2022

CEO, President & Director exercised options and sold US$103k worth of stock